Previous 10 | Next 10 |
Biopharmaceutical stocks have undergone a dramatic correction over the past six months, with the XBI declining by 45%. The decline was appropriate, given the number of companies that went public in 2021 with preclinical data and a valuation exceeding $1 billion. Not only would the...
Cryoport is not just any biotech company, as it is banking on the booming logistic businesses for the cell/gene therapy sector. Leveraging the powerful merger and acquisition approach, Cryoport has been enjoying leaping top-line growth year-over-year. Despite a temporary setback, ...
The following slide deck was published by Cryoport, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Cryoport, Inc. 2022 Q1 - Results - Earnings Call Presentation
Cryoport, Inc. (CYRX) Q1 2022 Earnings Conference Call May 05, 2022 05:00 PM ET Company Participants Todd Fromer - President, KCSA Strategic Communications Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - CSO Conference Call Participants John Sourbeer - UBS Brandon Couillard - Je...
CryoPort press release (NASDAQ:CYRX): Q1 GAAP EPS of -$0.31 misses by $0.09. Revenue of $52.3M (-1.8% Y/Y) misses by $0.56M. Provides Full Year 2022 Revenue Guidance of $260-$265 million vs. $257.31M. For further details see: CryoPort GAAP EPS of -$0.31 misses by $0.09, revenue of $52.3...
Cryoport Reports First Quarter 2022 Results PR Newswire Revenue of $52.3 million Provides Full Year 2022 Revenue Guidance of $260 - $265 million Expansion and advancement of robust clinical pipeline continues – now supporting a reco...
Cryoport to Report First Quarter 2022 Financial Results on May 5, 2022 PR Newswire NASHVILLE, Tenn. , April 28, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain s...
A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company's growth by acquisition strategy. There are also management changes and the...
Cryoport (NASDAQ:CYRX), a provider of logistics and supply chain solutions for the life sciences industry, on Monday said it acquired Cell&Co BioServices, a business providing biorepository, kitting, and logistics services. CYRX's purchase price for Cell&Co was €6.2M, comprised...
Cryoport Acquires Cell&Co BioServices Cryoport Acquires Cell&Co BioServices PR Newswire Acquisition of Cell&Co BioServices, Clermont-Ferrand , France, accelerates Company's EMEA expansion plans and development of its Global Supply Chain Network...
News, Short Squeeze, Breakout and More Instantly...
Cryoport to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire NASHVILLE, Tenn. , July 23, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sci...
A look at the top 10 most actives in the United States GlycoMimetics Inc. (GLYC) rose 42.5% to $0.38 on volume of 73,016,681 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.16 on volume of 71,818,174 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 25.4% to $0.2431 on volume...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.7% to $118.11 on volume of 457,565,587 shares Agrify Corporation (AGFY) rose 68.7% to $0.4251 on volume of 291,898,257 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 13.7% to $0.3662 on volume...